A Phase 2 interventional study of Dupilumab and Placebo (for Dupilumab) in Asthma, sponsored by Sanofi. Completed at 50 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-08.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 19th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 2, and was the 1st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2011.
This study's enrollment of 104 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2011, is one of 11 in phase 2, and was the 10th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma.
Secondary Objectives:
The total duration of the study period per participant was 20-22 weeks broken down as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Medical diagnosis of persistent asthma for at least 12 months whose:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
Drug: Placebo (for Dupilumab) · Drug: Fluticasone/Salmeterol combination therapy · Drug: Fluticasone monotherapy · Drug: Albuterol · Drug: Levalbuterol
Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
Drug: Dupilumab · Drug: Fluticasone/Salmeterol combination therapy · Drug: Fluticasone monotherapy · Drug: Albuterol · Drug: Levalbuterol
Solution for injection, one subcutaneous injection.
Also known as: SAR231893, REGN668
Solution for injection, one subcutaneous injection.
Drug pages: Fluticasone · Salmeterol Xinafoate
Oral inhalation twice daily.
Oral inhalation twice daily.
Oral inhalation as needed.
Oral inhalation as needed.
Percentage of Participants With Asthma Exacerbation
An asthma exacerbation was defined as the occurrence of any of the following: ≥30% reduction from baseline in morning PEF on 2 consecutive days; or ≥6 additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; or deterioration of asthma, as determined by the investigator, requiring systemic steroid treatment, or an increase in inhaled corticosteroid (ICS) of ≥4 times the last dose received prior to discontinuation from the study, or hospitalization. The occurrence of asthma exacerbations by individual criteria are reported.
Time frame: Baseline up to Week 12
Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12
The time-to-asthma exacerbation was defined as the time from the date of randomization to the date of the first asthma exacerbation event; for participants without asthma exacerbation, it was censored at the end of treatment visit date. The median time to first asthma exacerbation was not estimated because the number of asthma exacerbations was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of asthma exacerbation at Week 4, 8 and 12, are presented as the descriptive measure statistics.
Time frame: Baseline up to Week 12
Percentage of Participants With Composite Asthma Events
Composite asthma event was defined as a 30% or greater reduction from baseline in morning PEF on 2 consecutive days together with 6 or more additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days.
Time frame: Baseline up to Week 12
Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.
Time frame: Baseline, Week 12
Change From Baseline in Peak Expiratory Flow (PEF) to Week 12
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.
Time frame: Baseline, Week 12
Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12
ACQ-5 questionnaire is a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score is the mean of the 5 questions and range between 0 (disease totally controlled) and 6 (disease severely uncontrolled), a higher score indicated lower asthma control.
Time frame: Baseline, Week 12
Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12
The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
Time frame: Baseline, Week 12
Change From Baseline in Morning Asthma Symptom Scores to Week 12
AM (ante meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning. No nighttime awakenings,2= Woke up once because of asthma (including early awakening),3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Time frame: Baseline, Week 12
Change From Baseline in Evening Asthma Symptom Scores to Week 12
PM (post meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the day. It ranges from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Time frame: Baseline, Week 12
Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12
Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.
Time frame: Baseline, Week 12
Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12
Number of Albuterol or Levalbuterol inhalations were recorded daily by the participants in their electronic diary as Albuterol or Levalbuterol was to be used only as needed for symptoms, not on a regular basis or prophylactically.
Time frame: Baseline, Week 12
The study was conducted at 50 sites in the United States. A total of 491 participants were screened between March 2011 and June 2012, of whom 104 were randomized at 28 sites. A total of 387 participants were screen failures mainly due to inclusion criteria for eosinophilic asthma not met.
| Milestone | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Started | 52 | 52 |
| Treated | 52 | 52 |
| Completed | 35 | 45 |
| Not completed | 17 | 7 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lack of efficacy | 11 | 1 |
| Withdrew: Poor compliance to protocol | 1 | 0 |
| Withdrew: Other than specified above | 2 | 3 |
An asthma exacerbation was defined as the occurrence of any of the following: ≥30% reduction from baseline in morning PEF on 2 consecutive days; or ≥6 additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; or deterioration of asthma, as determined by the investigator, requiring systemic steroid treatment, or an increase in inhaled corticosteroid (ICS) of ≥4 times the last dose received prior to discontinuation from the study, or hospitalization. The occurrence of asthma exacerbations by individual criteria are reported.
| percentage of participants | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Asthma exacerbation | 44.2 | 5.8 |
| ≥30% reduction from baseline in morning PEF | 19.2 | 1.9 |
| ≥6additional albuterol/levalbuterol puffs | 19.2 | 1.9 |
| Systemic steroid treatment | 9.6 | 1.9 |
| Increase in ICS ≥4 times baseline dose of ICS | 5.8 | 0.0 |
| Hospitalization | 0.0 | 0.0 |
The time-to-asthma exacerbation was defined as the time from the date of randomization to the date of the first asthma exacerbation event; for participants without asthma exacerbation, it was censored at the end of treatment visit date. The median time to first asthma exacerbation was not estimated because the number of asthma exacerbations was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of asthma exacerbation at Week 4, 8 and 12, are presented as the descriptive measure statistics.
| Probability of asthma exacerbation | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Probability at Week 4 | 0.058 (0.000 to 0.122) | 0.038 (0.000 to 0.091) |
| Probability at Week 8 | 0.245 (0.124 to 0.366) | 0.058 (0.000 to 0.121) |
| Probability at Week 12 | 0.460 (0.318 to 0.602) | 0.058 (0.000 to 0.121) |
Composite asthma event was defined as a 30% or greater reduction from baseline in morning PEF on 2 consecutive days together with 6 or more additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days.
| percentage of participants | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Percentage of Participants With Composite Asthma Events | 1.9 | 0 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.
| Liters | Placebo | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12 | -0.12 ± 0.35 | 0.06 ± 0.32 |
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.
| liters/minute | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Change in morning PEF | -11.2 ± 66.1 | 10.6 ± 48.5 |
| Change in evening PEF | -15.6 ± 70.7 | -3.4 ± 49.3 |
ACQ-5 questionnaire is a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score is the mean of the 5 questions and range between 0 (disease totally controlled) and 6 (disease severely uncontrolled), a higher score indicated lower asthma control.
| units on a scale | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12 | -0.50 ± 1.12 | -1.07 ± 0.94 |
The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
| units on a scale | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12 | 1.27 ± 15.85 | -9.17 ± 15.40 |
AM (ante meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning. No nighttime awakenings,2= Woke up once because of asthma (including early awakening),3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
| units on a scale | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Morning Asthma Symptom Scores to Week 12 | 0.3 ± 0.7 | -0.4 ± 0.7 |
PM (post meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the day. It ranges from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
| units on a scale | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Evening Asthma Symptom Scores to Week 12 | 0.1 ± 0.9 | -0.5 ± 0.6 |
Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.
| number of awakenings/day | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12 | 0.1 ± 0.7 | -0.3 ± 0.7 |
Number of Albuterol or Levalbuterol inhalations were recorded daily by the participants in their electronic diary as Albuterol or Levalbuterol was to be used only as needed for symptoms, not on a regular basis or prophylactically.
| number of inhalations/day | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12 | 0.4 ± 2.4 | -1.3 ± 1.7 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (for Dupilumab) | 0/52 (0%) | 3/52 (5.8%) | 24/52 (46.2%) |
| Dupilumab 300 mg qw | 0/52 (0%) | 1/52 (1.9%) | 33/52 (63.5%) |
| Event | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| PneumoniaInfections and infestations | 1/52 | 0/52 |
| Bipolar disorderPsychiatric disorders | 0/52 | 1/52 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/52 | 0/52 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/52 | 0/52 |
| Ankle fractureInjury, poisoning and procedural complications | 1/52 | 0/52 |
| Gun shot woundInjury, poisoning and procedural complications | 1/52 | 0/52 |
| Event | Placebo (for Dupilumab) | Dupilumab 300 mg qw |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/52 | 7/52 |
| NasopharyngitisInfections and infestations | 2/52 | 7/52 |
| HeadacheNervous system disorders | 3/52 | 6/52 |
| SinusitisInfections and infestations | 5/52 | 1/52 |
| Injection site painGeneral disorders | 3/52 | 5/52 |
| Injection site reactionGeneral disorders | 0/52 | 5/52 |
| NauseaGastrointestinal disorders | 1/52 | 4/52 |
| Gastroenteritis viralInfections and infestations | 3/52 | 0/52 |
| Viral upper respiratory tract infectionInfections and infestations | 0/52 | 3/52 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/52 | 3/52 |
Baseline participants included all randomized participants.
| Age, Continuous(years) | Placebo (for Dupilumab) | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 41.6 ± 13.1 | 37.8 ± 13.2 | 39.7 ± 13.2 |
| Sex: Female, Male(Participants) | Placebo (for Dupilumab) | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Female | 26 | 26 | 52 |
| Male | 26 | 26 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (for Dupilumab) | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 12 | 16 |
| Not Hispanic or Latino | 48 | 40 | 88 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race(Participants) | Placebo (for Dupilumab) | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Caucasian/White | 38 | 45 | 83 |
| Black | 9 | 5 | 14 |
| Asian/Oriental | 3 | 1 | 4 |
| Other than specified above | 2 | 1 | 3 |
| Prior ICS/LABA Combination Therapy Dose(Participants) | Placebo (for Dupilumab) | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| High Dose | 41 | 42 | 83 |
| Medium Dose | 11 | 10 | 21 |
| Morning Peak Expiratory Flow (PEF)(L/min) | Placebo (for Dupilumab) | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 406.87 ± 110.74 | 393.04 ± 101.13 | 400.02 ± 105.80 |
| Number of Inhalations of Albuterol or Levalbuterol in a 24-hour Period(number of inhalations) | Placebo (for Dupilumab) | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 2.04 ± 1.78 | 2.16 ± 2.40 | 2.10 ± 2.10 |
The record gives a start of Mar 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 4 years 8 months after primary completion. A results delay was requested in Dec 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab